Merrion partners with Novo Nordisk on oral insulin formulations
DUBLIN , Ireland An Irish drug maker has announced a partnership with Denmark’s Novo Nordisk to develop orally administered formulations of insulin analogues for the treatment of diabetes.
Merrion Pharmaceuticals said Monday that it had entered a development and license agreement with Novo Nordisk to develop oral formulations of the Danish drug maker’s proprietary insulin analogues using Merrion’s GIPET pill technology.
Under the agreement, Novo Nordisk will fund the development and commercialization of drug candidates, while Merrion will take responsibility for the development and manufacture of the initial clinical batches. A joint development committee will oversee the two companies’ work.
Merrion will receive up to $58 million for the first product developed under the agreement that reaches the market, based on development, regulatory and sales milestones, as well as royalties on sales.
J&J announces tender offer to buyout Omrix Biopharma stock
NEW BRUNSWICK, N.J. Johnson & Johnson said Tuesday that it would be making a tender offer to purchase all outstanding shares of common stock of New York-based biotech Omrix Biopharmaceuticals in an offer worth about $438 million in cash.
Upon the successful closing of the offer, Omrix stockholders will receive $25 per share of Omrix common stock tendered in the offer, minus required holding taxes. Omrix will operate as a stand-alone company reporting through Johnson & Johnson subsidiary Ethicon.
J&J said it would file a tender offer statement with terms of the offer with the Securities and Exchange Commission. The offer will expire at midnight on Dec. 23.
CVS Caremark, MinuteClinic working overtime to disseminate flu shots
WOONSOCKET, R.I. CVS Caremark is working toward its previously announced goal of delivering one million flu vaccinations this year and as part of that effort has kicked off an advertising campaign to inform consumers about CVS Caremark’s integrated flu vaccination offerings, not to mention drive awareness of the MinuteClinic model.
The “Flu Shots Made Simple” campaign began in September and will run through Dec. 31. It is a multi-faceted campaign that includes in-store signage and store radio spots, a national television campaign promoting joint CVS/pharmacy and MinuteClinic flu shot services, a MinuteClinic-dedicated TV campaign in select markets, newspaper ads in select markets, direct mail to target consumers and public relation efforts.
The goal: To inform consumers about CVS Caremark’s integrated flu vaccination offering which includes MinuteClinic locations, pharmacist-administered shots and scheduled flu shot clinics within select CVS/pharmacy locations.
“Flu shots have always been a key service of CVS and MinuteClinic. We had the opportunity this year to align MinuteClinic’s flu shot capabilities with other flu vaccination services offered at CVS/pharmacy. It is a natural point of integrated services within CVS Caremark,” said Melissa Studzinski, director of marketing for MinuteClinic.
While the campaign runs through Dec. 31, flu shots will continue to be available at all 559 MinuteClinic locations on demand throughout the flu season, which could run as late as March or April.
As part of the campaign, the company has created a flu shot voucher program for Caremark clients whereby participating members are eligible to receive a flu shot at MinuteClinic with no out-of-pocket cost to them, noted Studzinski.